

# INPLASY PROTOCOL

To cite: Sun et al. Efficacy Evaluation of Acupoint Therapy on the Improvement of Cognitive Function in Patients with Mild Cognitive Impairment: A Protocol for a Systematic Review and Meta-analysis. Inplasy protocol 202340001. doi: 10.37766/inplasy2023.4.0001

Received: 01 April 2023

Published: 01 April 2023

**Corresponding author:**  
Beijie Sun

sunbeijie2000@foxmail.com

**Author Affiliation:**  
Longhua Hospital, Shanghai  
University of Traditional  
Chinese Medicine.

**Review Stage at time of this submission:** Formal screening of search results against eligibility criteria.

**Conflicts of interest:**  
None declared.

## Efficacy Evaluation of Acupoint Therapy on the Improvement of Cognitive Function in Patients with Mild Cognitive Impairment: A Protocol for a Systematic Review and Meta-analysis

Sun, BJ<sup>1</sup>; Fu, QH<sup>2</sup>; Lau, YYG<sup>3</sup>.

**Review question / Objective:** To delineate the evidence base from randomized controlled trials on mild cognitive impairment (MCI) patients with the treatment of acupoint therapy.

**Condition being studied:** Mild cognitive impairment (MCI) is an intermediate state between normal aging-induced cognitive decline and dementia. It is characterized by impairment in single or multiple cognitive domains, including memory, executive function, language comprehension and expression, etc. Cognitive function of MCI patients will probably continue to decline and eventually develop into dementia. Early intervention for MCI can reduce the risk of dementia and delay the deterioration of cognitive function. Since drug therapy has no definite efficacy on improving cognitive function of MCI patients at present, non-pharmacological interventions are particularly important in the treatment of MCI. As a representative non-pharmacological intervention in traditional Chinese medicine, acupoint therapy is promising in the treatment of MCI.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 01 April 2023 and was last updated on 29 February 2024 (registration number INPLASY202340001).

### INTRODUCTION

**Review question / Objective:** To delineate the evidence base from randomized controlled trials on mild cognitive impairment (MCI) patients with the treatment of acupoint therapy.

**Condition being studied:** Mild cognitive impairment (MCI) is an intermediate state between normal aging-induced cognitive decline and dementia. It is characterized by impairment in single or multiple cognitive domains, including memory, executive function, language comprehension and expression, etc. Cognitive function of MCI

patients will probably continue to decline and eventually develop into dementia. Early intervention for MCI can reduce the risk of dementia and delay the deterioration of cognitive function. Since drug therapy has no definite efficacy on improving cognitive function of MCI patients at present, non-pharmacological interventions are particularly important in the treatment of MCI. As a representative non-pharmacological intervention in traditional Chinese medicine, acupoint therapy is promising in the treatment of MCI.

## METHODS

**Participant or population:** Adults with a clinical diagnosis of MCI are the population of interest. The diagnostic criteria must be in accordance with accepted standards such as Peterson criteria (2004), NIA-AA criteria (2011), etc. MCI patients with a definite cause that influence cognitive function, such as cerebrovascular disease, Parkinson's disease, etc., will be excluded.

**Intervention:** Patients in the experimental group needed to have received at least one type of acupoint therapy, including but not limited to acupuncture, electro-acupuncture, warm acupuncture, moxibustion, acupoint massage, etc. Acupoint therapy could be used alone or in combination with other non-pharmacological interventions for enhancing cognitive function such as cognitive training, transcranial direct current stimulation, etc. At the same time, the intervention of the experimental group could be combined with the same therapy as the control group, e.g., acupuncture + cognitive training / cognitive training. Studies with drug therapy or dietary supplement targeted to improve cognitive function in the experimental group will be excluded.

**Comparator:** The population of the control group must be diagnosed with MCI. Interventions of the control group could be treatments without acupoint therapy, sham intervention, health education, blank or waiting group.

**Study designs to be included:** Randomized controlled trials.

**Eligibility criteria:** The inclusion criteria were as follows: (1) Population: Adults clinically diagnosed with MCI. The diagnostic criteria must be in accordance with recognized standards such as Peterson2004, NIA-AA2011, etc. (2) Intervention: ① At least one type of acupoint therapy, including but not limited to acupuncture, electroacupuncture, warm acupuncture, moxibustion, acupoint massage, etc. ② Acupoint therapy could be used alone or in combination with other non-pharmacological interventions for enhancing cognitive function such as cognitive training, transcranial direct current stimulation, etc. (3) Comparison: Interventions of the control group could be treatments without acupuncture therapy, sham intervention, health education, blank or waiting group. And the studies must contain MCI adults only. (4) Outcomes: Including at least one of following outcomes: ① Montreal cognitive assessment (MoCA); ② Mini-mental state examination (MMSE). (5) Study Design: ① Randomized controlled trial. ② The language should be limited to Chinese and English. The exclusion criteria were as follows: (1) Secondary cognitive impairment; (2) Studies with drug therapy or dietary supplement in the trial group; (3) Duplicate data; (4) Non-core journal literature; (5) Conference materials; (6) Academic dissertations; (7) Literature not ethically cleared.

**Information sources:** Pubmed, Cochrane Library, CNKI, VIP, Wanfang Data and CBM.

**Main outcome(s):** Including at least one of following outcomes: ① Montreal cognitive assessment (MoCA); ② Mini-mental state examination (MMSE).

**Additional outcome(s):** Depending on the situation, we may select other scales, biomarker test results and neuroimaging test results as additional outcomes.

---

**Quality assessment / Risk of bias analysis:**

The risk of bias of each study in this review will be assessed using the Cochrane Handbook for Systematic Reviews of Interventions. Random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias will be evaluated as low, unclear, or high risk of bias.

**Strategy of data synthesis:** We will pool data whenever possible and appropriate. If we judge meta-analyses unsuitable, we will use a narrative description. If we judge meta-analyses suitable, we will use Review Manager (Revman) version 5.4.1 to analyze the research data. Regarding to continuous variables, mean difference (MD) will be selected as the combined statistics, and each effect quantity will be expressed with 95% CI. Analysis will be carried out using a fixed or random effects model according to the heterogeneity. The level of heterogeneity in the study depends on the  $I^2$  statistic, larger values indicating increased heterogeneity.  $P < 0.1$  will be regarded as statistical heterogeneity and prompts random effects modelling after excluding the influence of obvious heterogeneity.

**Subgroup analysis:** If necessary, each of the outcomes will be conducted subgroup such as moxibustion group, electroacupuncture group, etc.

**Sensitivity analysis:** Sensitivity analysis will be used to assess the robustness of the meta-analysis results and will be performed if there is significant heterogeneity among studies.

**Country(ies) involved:** China.

**Keywords:** Mild cognitive impairment; acupoint therapy; acupuncture; systematic review.

**Contributions of each author:**

Author 1 - Beijie Sun.

Email: sunbeijie2000@foxmail.com

Author 2 - Qinhui Fu.

Email: ff777315@163.com

Author 3 - Yew Yen Grace Lau.

**Support:** This work was supported by the key Scientific Research Program of The Science and Technology Commission of Shanghai Municipality (22Y11922900, 18401970500).